QT prolongation is associated with increased mortality in end stage liver disease

Table 1 Patient characteristics n (%)

Variable	QTc prolongation			No QTc prolongation
	All (n = 207)	Male (n = 150)	Female (n = 57)	All (n = 199)	Male (n = 92)	Female (n = 107)
Beta-blocker use1	161 (77.8)	122 (81.3)	39 (68.4)	153 (77.7)	66 (71.7)	87 (82.9)3
Viral etiology	80 (38.7)	65 (43.3)	15 (26.3)	69 (34.7)	42 (45.7)	27 (25.2)
Ethanol etiology	90 (43.5)	78 (52.0)	12 (21.1)	68 (34.2)	46 (50.0)	22 (20.6)
Non-alcohol steatohepatitis etiology	47 (22.7)	28 (18.7)	19 (33.3)	57 (28.6)	13 (14.1)	44 (41.1)
Viral and ethanol etiology	35 (16.9)	32 (21.3)	3 (5.3)	24 (12.1)	17 (18.5)	7 (6.5)
Sodium2	135.6 + 6.2	135.4 + 6.4	136.3 + 5.3	136.2 + 5.6	135.4 + 5.6	136.9 + 5.6
INR2 (logarithm)	0.39 + 0.32	0.39 + 0.32	0.37 + 0.31	0.35 + 0.34	0.31 + 0.26	0.39 + 0.39
Creatinine2 (logarithm)	0.39 + 0.51	0.43 + 0.50	0.30 + 0.53	0.30 + 0.43	0.29 + 0.403	0.31 + 0.46
Bilirubin2 (logarithm)	1.19 + 1.05	1.18 + 1.07	1.20 + 0.99	1.06 + 0.96	0.90 + 0.86	1.20 + 1.03
MELD-NA2	21.0 + 9.5	21.6 + 9.5	19.5 + 9.3	19.3 + 9.1	18.6 + 7.73	19.8 + 10.2
MELD2	19.0 + 9.6	19.4 + 9.7	18.0 + 9.3	17.3 + 9.0	16.0 + 7.23	18.3 + 10.1
Age	56.1 + 9.1	56.2 + 8.8	56.0 + 9.7	56.7 + 9.0	56.3 + 9.3	57.0 + 8.7

Entries are number (percent) or mean + SD.

¹Excluded for two subjects;

²Excluded for 102 subjects;

³Significantly different (P < 0.05) vs patients of same gender with QT_c prolongation.